BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Britain Courts Anthropic Amid US Defense Department Dispute 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
ROCKVILLE, Md., Nov. 11, 2016 -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a business update call on Monday, November 14, 2016 at 9:00AM EST.
Jack Khattar, President and Chief Executive Officer, and Greg Patrick, Chief Financial Officer, will host a conference call to present a business update. Following the presentation, the call will be open for questions.
A live webcast will be available at www.supernus.com.
Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.
| Conference dial-in: | (877) 288-1043 | |||
| International dial-in: | (970) 315-0267 | |||
| Conference ID: | 3132501 | |||
| Conference Call Name: | Supernus Pharmaceuticals 3Q 2016 Business Update Conference Call | |||
Following the live call, a replay will be available on the Company's website under the 'Investors' section. The webcast will be available on the Company's website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of impulsive aggression in ADHD patients and SPN-812 for the treatment of ADHD.
CONTACTS: Jack A. Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc. Tel: (301) 838-2591 or INVESTOR CONTACT: Peter Vozzo Westwicke Partners Office: (443) 213-0505 Mobile: (443) 377-4767 Email: [email protected]
